Analyzing Exelixis (EXEL) Stock – A Fundamental Overview

By Naomi Wentworth • Saturday, January 11 10:12 • Permanent Link

Shares of Biotechnology company Exelixis jumped 4.4% today. With many investors piling into EXEL without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Exelixis has moved 59.8% over the last year, and the S&P 500 logged a change of 22.3%
EXEL has an average analyst rating of buy and is 4.49% away from its mean target price of $34.47 per share
Its trailing earnings per share (EPS) is $1.55
Exelixis has a trailing 12 month Price to Earnings (P/E) ratio of 23.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.7 and its forward P/E ratio is 21.2
The company has a Price to Book (P/B) ratio of 4.52 in contrast to the S&P 500's average ratio of 4.74
Exelixis is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
EXEL has reported YOY quarterly earnings growth of 12169.9% and gross profit margins of 1.0%
The company has a free cash flow of $431.27 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.